FROM MEDSCAPE:
"The FDA has given accelerated approval to ibrutinib (Imbruvica) for
treating CLL in patients who have undergone at least 1 previous therapy.
Approval was granted based on the findings of a clinical study of 48
previously treated patients who were diagnosed with CLL, on average, 6.7
years before the study. The patients had an overall response rate of
nearly 58%, with a duration of response from 5.6 to 24.2 months. The
most common adverse effects observed in the study included
thrombocytopenia, diarrhea, bruising, neutropenia, anemia, and upper
respiratory tract infection. Ibrutinib was also approved for treating
mantle cell lymphoma in 2013."
================================THIS DRUG IS JUST WONDERFUL, ATTESTING TO THE STRENGTH AND IMPORTANCE OF THIS RECEPTOR IN LYMPHOCYTE RELATED PROLIFERATIONS.....=================
No comments:
Post a Comment